

Minoxidil and Its Use in Hair Disorders: A Review [Corrigendum]

Suchonwanit P, Thammarucha S, Leerunyakul K. *Drug Des Devel Ther.* 2019;13:2777–2786.

On page 2781, Androgenetic alopecia section, last paragraph, “A combination of low-dose minoxidil 2.5 mg and spironolactone 25 mg in patients with FPHL showed preferable outcomes with decrease hair shedding and improved hair density. The mean severity score reduced to 2.3 at 6 months and 2.6 at 12 months. Mild adverse effects including urticaria, postural hypotension, and facial hypertrichosis were reported.” should read “A combination of low-dose minoxidil 0.25 mg and spironolactone 25 mg in patients with

FPHL showed preferable outcomes with decrease hair shedding and improved hair density. Mean reduction in hair shedding score was 2.3 at 6 months and 2.6 at 12 months. Mild adverse effects including urticaria, postural hypotension, and facial hypertrichosis were reported.”

Following feedback from a reader, we found 1) the incorrect dosage was listed for minoxidil and 2) the reduction in severity score relates to the visual-analogue Sinclair hair shedding scale.

The authors apologize for these errors.

Publish your work in this journal

Drug Design, Development and Therapy is an international, peer-reviewed open-access journal that spans the spectrum of drug design and development through to clinical applications. Clinical outcomes, patient safety, and programs for the development and effective, safe, and sustained use of medicines are a feature of the journal, which has also

been accepted for indexing on PubMed Central. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/drug-design-development-and-therapy-journal>